[go: up one dir, main page]

AR008267A1 - Pirroles sustituidos. - Google Patents

Pirroles sustituidos.

Info

Publication number
AR008267A1
AR008267A1 ARP970103309A ARP970103309A AR008267A1 AR 008267 A1 AR008267 A1 AR 008267A1 AR P970103309 A ARP970103309 A AR P970103309A AR P970103309 A ARP970103309 A AR P970103309A AR 008267 A1 AR008267 A1 AR 008267A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
aralkyl
hydrogen
independently
Prior art date
Application number
ARP970103309A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR008267A1 publication Critical patent/AR008267A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Los compuestos de la fórmula I; R y R con independencia entre sí son alquilo, arilo, alquenilo, alquinilo; R y R con independencia entre sí sonhidrógeno o alquilo; R4, R5, R6 y R7 con independencia entre sí son CH300CR8, CO2R9, CH2OR10, CHO,CH 2NR11R12, CON(R13)2, hidrógeno, halógeno, ciano,alquilo, hidroxi, alcoxi, ariloxi, haloaquilo, nitro, amino, acilamino, aralquiloxi, monoalquilamino, dialquilamino, alquiltio, alquilsulfinilo oalquilsulonilo, con la condición de que porlo me nos uno de R4, R5, R6, o R7 sea ciano, CH2OOCR8, CO2R9, CH2OR10, CH2NR11R12, CHO o CON(R13)2; R8 esalquilo, aralquilo o arilo; R9 es alquilo, aralquilo o arilo; R10 es hidrógeno, alquilo, aralquilo o arilo; R11 y R12 con independencia entresí hid rógneo,alquilo, arilo, aralquilo o acilo; R13 es hidrógeno, alquilo, arilo, o aralquilo; y uno de X e Y significa O y el otro significa O, S, (H, OH) o(H, H); así como los productos previos farmacéuticamente aceptables de loscompuestos ácidos de la fórmula I con bases y/o de los compuestos básicos de lafórmula I con ácidos son agentes antiproliferativos útiles para el tratamiento del cancer.
ARP970103309A 1996-07-29 1997-07-22 Pirroles sustituidos. AR008267A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2207996P 1996-07-29 1996-07-29

Publications (1)

Publication Number Publication Date
AR008267A1 true AR008267A1 (es) 1999-12-29

Family

ID=21807711

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970103309A AR008267A1 (es) 1996-07-29 1997-07-22 Pirroles sustituidos.

Country Status (23)

Country Link
US (2) US5856517A (es)
EP (1) EP0915872B1 (es)
JP (1) JP2000516589A (es)
KR (1) KR20000029637A (es)
CN (2) CN1495182A (es)
AR (1) AR008267A1 (es)
AT (1) ATE240318T1 (es)
AU (1) AU739742B2 (es)
BR (1) BR9711605A (es)
CA (1) CA2262092A1 (es)
CO (1) CO4900055A1 (es)
CY (1) CY2483B1 (es)
DE (1) DE69722003T2 (es)
DK (1) DK0915872T3 (es)
ES (1) ES2198001T3 (es)
HR (1) HRP970414A2 (es)
MA (1) MA24287A1 (es)
PE (1) PE91698A1 (es)
PT (1) PT915872E (es)
SA (1) SA97180473A (es)
TR (1) TR199900157T2 (es)
WO (1) WO1998004552A1 (es)
ZA (1) ZA976492B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127500C (zh) * 1998-03-17 2003-11-12 弗·哈夫曼-拉罗切有限公司 抑制细胞增殖的取代双吲哚基马来酰亚胺
US6743785B2 (en) * 1999-12-16 2004-06-01 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
EP1250334B1 (en) * 1999-12-16 2004-05-19 Eli Lilly And Company Medicaments useful for the treatment of proliferative diseases
AU2072201A (en) 1999-12-16 2001-06-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
US6281356B1 (en) 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
AR040083A1 (es) * 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
JP4171061B2 (ja) 2005-02-09 2008-10-22 アーキュール,インコーポレーテッド マレイミド誘導体、医薬組成物、および癌の治療のためのその使用
ES2410955T3 (es) * 2006-12-19 2013-07-04 Novartis Ag Derivados de indolilmaleimida como inhibidores de la quinasa
WO2009002806A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
KR20100024494A (ko) 2007-06-22 2010-03-05 아르퀼 인코포레이티드 퀴나졸리논 화합물 및 이의 사용 방법
ATE522531T1 (de) 2007-06-22 2011-09-15 Arqule Inc Indolylpyrrolidine zur behandlung von krebs
JP2009035537A (ja) * 2007-07-10 2009-02-19 Nippon Synthetic Chem Ind Co Ltd:The N−置換アニリン誘導体及び1−置換インドール誘導体の製造方法
FR2927075A1 (fr) * 2008-02-04 2009-08-07 Centre Nat Rech Scient Molecules comprenant un squelette bis-(heteroaryl)maleimide, et leur utilisation dans l'inhibition d'enzymes
GB201111427D0 (en) * 2011-07-05 2011-08-17 Amakem Nv Novel bisindolylmaleimides, pan-pkc inhibitors
CA2939219C (en) 2014-02-11 2023-02-28 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
EP3169337A1 (en) 2014-07-17 2017-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
WO2018237145A1 (en) * 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
PT93947B (pt) * 1989-05-05 1996-11-29 Goedecke Ag Processo para a preparacao de novos derivados de maleinimidas e de composicoes farmaceuticas que os contem
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
JPH0539289A (ja) * 1991-02-15 1993-02-19 Masahiro Irie 無水マレイン酸誘導体およびその製造方法
EP0630241A1 (en) * 1992-03-20 1994-12-28 The Wellcome Foundation Limited Indole derivatives with antiviral activity
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung

Also Published As

Publication number Publication date
US6030994A (en) 2000-02-29
DK0915872T3 (da) 2003-09-08
PT915872E (pt) 2003-09-30
ZA976492B (en) 1998-01-29
KR20000029637A (ko) 2000-05-25
CY2483B1 (en) 2005-06-03
ATE240318T1 (de) 2003-05-15
CO4900055A1 (es) 2000-03-27
CA2262092A1 (en) 1998-02-05
AU3769097A (en) 1998-02-20
WO1998004552A1 (en) 1998-02-05
SA97180473A (ar) 2005-12-03
DE69722003D1 (de) 2003-06-18
TR199900157T2 (xx) 1999-04-21
JP2000516589A (ja) 2000-12-12
EP0915872A1 (en) 1999-05-19
CN1495182A (zh) 2004-05-12
CN1226247A (zh) 1999-08-18
BR9711605A (pt) 1999-08-24
MA24287A1 (fr) 1998-04-01
US5856517A (en) 1999-01-05
DE69722003T2 (de) 2004-04-01
AU739742B2 (en) 2001-10-18
EP0915872B1 (en) 2003-05-14
PE91698A1 (es) 1998-12-24
ES2198001T3 (es) 2004-01-16
CN1151149C (zh) 2004-05-26
HRP970414A2 (en) 1998-06-30

Similar Documents

Publication Publication Date Title
AR008267A1 (es) Pirroles sustituidos.
AR007969A1 (es) Compuestos derivados de pirroles sustituidos, su utilizacion y composiciones farmaceuticas que contienen tales compuestos
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
ES2193508T3 (es) Ftalizinonas.
EA199700061A1 (ru) Способ получения силденафила
ATE219938T1 (de) Neue 4-arylpiperazine und 4-arylpiperidine
ES2100907T3 (es) Bencimidazoles, medicamentos que contienen estos compuestos y proced imiento para su preparacion.
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
ATE106401T1 (de) Benzodiazepin-analoge.
ES2148476T3 (es) Derivados de azabicicloalcano n-substituidos como neurolepticos asf.
ES2045180T3 (es) Nuevo procedimiento para la obtencion de 4-aciloxi-3-hidroxietil-azetidinonas.
AR241531A1 (es) Un procedimiento para la preparacion derivados de 2-indolinona, y sus sales farmaceuticamente aceptables.
DK0971922T3 (da) Tetrahydropyrido-forbindelser
ATE181737T1 (de) Cck oder gastrin modulierende 5-heterocyclicyl- 1,5-benzodiazepine
ES2196069T3 (es) Derivados morfinoides condensados con heterociclos.
ES2075976T3 (es) Derivados de aminoacido y su empleo como agentes antiviricos.
ES2167721T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica.
MX9700854A (es) Derivados de azabicicloheptano n-substituidos utiles como neurolepticos.
ES2077867T3 (es) 3-carbamoil-4-hidroxicumarinas antihelminticas y anticoccidiales, procedimiento de uso y composiciones.
PE20040786A1 (es) Derivados de 7h-dibenzo[b,g][1,5]dioxocin-5-ona como inhibidores de la proteina transportadora del colesterol esterificado (cetp)
ECSP972205A (es) Pirroles sustituidos
AR010200A1 (es) Derivados de aza-antraciclinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ECSP972206A (es) Pirroles sustituidos
ATE106882T1 (de) Thioxanthenon-antitumormittel.
DK0967986T3 (da) Anvendelse af humant alfa1-surt glycoprotein til fremstilling af et farmaceutisk præparat

Legal Events

Date Code Title Description
FA Abandonment or withdrawal